QoL Deserves More Than a Footnote in Cancer Trials

A new review urges oncology researchers to treat patient-reported outcomes as core trial endpoints — not just secondary stats.
Medscape Medical News

source https://www.medscape.com/viewarticle/qol-deserves-more-than-footnote-cancer-trials-2025a1000jbv?src=rss

Comments

Popular posts from this blog

RA and RA-ILD Linked to Higher Lung Cancer Risk

New AAFP practice guideline sets blood pressure targets for adults with hypertension